Trauma Management in the End-Stage Renal Disease Patient

Blake, Anna-Maria; Toker, Steven I.; Dickerman, Richard; Dunn, Ernest L.
May 2002
American Surgeon;May2002, Vol. 68 Issue 5, p425
Academic Journal
More than 230,000 patients in the United States are being treated for end-stage renal disease (ESRD). This group of patients has not been evaluated for trauma resource use. When these patients are involved in trauma the need for dialysis and awareness of chronic disease processes must be considered in addition to their injuries. There were 4,894 patients admitted to a Level II trauma center over a 4-year period. Fifty-nine of these patients were considered to have ESRD before admission. The charts of these patients were reviewed and compared with those in the general trauma population. The average age of the ESRD patients was 58 years with an average Injury Severity Score of 8 as compared with 31 years of age and Injury Severity Score of 10.9 for the general trauma population. Thirty-four patients required hemodialysis within 48 hours of admission. Ten patients required mechanical ventilation. Eight patients in this study died. The complication and mortality rates among the ESRD patients were 50.8 per cent and 13.5 per cent respectively as compared with 16.3 and 4.7 per cent among the general trauma population. The trauma complication and mortality rates among ESRD patients are approximately three times greater than those in the general trauma population. Because of their coexisting medical problems and the need for dialysis trauma patients with ESRD should be cared for in trauma centers with dialysis capability and access to multidisciplinary services.


Related Articles

  • Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran. Mitra Mahdavi-Mazdeh; Mahnaz Zamyadi; Mohsen Nafar // Nephrology Dialysis Transplantation;Jan2008, Vol. 23 Issue 1, p288 

    Background. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are emerging as globally important public health problems, and will necessitate improvements in health-care policy. ESRD incidence/prevalence data are not available from large parts of the developing world. The main...

  • The effects of discontinuing cinacalcet at the time of kidney transplantation. Jadoul, Michel; Baños, Ana; Zani, Valter J.; Hercz, Gavril // NDT Plus;Feb2010, Vol. 3 Issue 1, p37 

    Background. The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on dialysis. Biochemical profiles and clinical outcomes in patients discontinuing cinacalcet at kidney transplantation have not been previously...

  • Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: The need for randomized trials. Al-Aly, Z. // Kidney International;Oct2007, Vol. 72 Issue 8, p909 

    Vitamin D has been used in the context of secondary hyperparathyroidism in patients with end-stage renal disease. A wave of recent studies suggests that vitamin D treatment may be associated with decreased mortality risk in these patients. The article by Wolf et al. further supports these...

  • Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kautzky-Willer, Alexandra; Pacini, Giovanni; Barnas, Ursula; Ludvik, Bernhard; Streli, Carola; Graf, Helmut; Prager, Rudolf // Kidney International;Jan1995, Vol. 47 Issue 1, p200 

    Recent studies suggest that secondary hyperparathyroidism and/or vitamin D deficiency are responsible for the insulin returnee in chronic renal failure. We investigated the effect of a 12-week intravenous treatment with 1,25 dihydroxycholecalciferol on glucose metabolism in 10 hemodialysis...

  • Renal Nutrition Update. STEIBER, ALISON L. // Renal & Urology News;Feb2011, Vol. 10 Issue 2, p11 

    The article examines various tools that are necessary in screening chronic kidney disease (CKD) patients for nutrition-related problems in the U.S. It highlights other factors affecting the implementation of such tools used at CDK and hemodialysis (HD) centers because of government funding...

  • The clinical status and survival in elderly dialysis: example of the oldest region of France. Glaudet, Florence; Hottelart, Carine; Allard, Julien; Allot, Vincent; Bocquentin, Frédérique; Boudet, Rémy; Champtiaux, Béatrice; Pierre Charmes, Jean; Ciobotaru, Monica; Dickson, Zara; Essig, Marie; Honoré, Philippe; Lacour, Céline; Lagarde, Christian; Manescu, Maria; Peyronnet, Pierre; Poux, Jean Michel; Rerolle, Jean Philippe; Rincé, Michel; Couchoud, Cécile // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: The number of elderly (≥75 years) patients with end-stage renal disease (ESRD) has increased markedly, including in the Limousin region, which has the oldest population in France. We retrospectively compared outcomes in elderly and non-elderly ESRD patients who started dialysis...

  • No impact of hyperkalaemia with renin–angiotensin system blockades in maintenance haemodialysis patients. Sang-Woong Han; Young-Woong Won; Joo-Hark Yi; Ho-Jung Kim // Nephrology Dialysis Transplantation;Apr2007, Vol. 22 Issue 4, p1150 

    Background. Renin–angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated...

  • The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Eschbach, Joseph W. // Kidney International;Jan1989, Vol. 35 Issue 1, p134 

    Presents a case of a 40-year-old man who has undergone chronic hemodialysis for seven years. Case history; Detection of proteinuria; Renal transplantation; Diagnosis of the hypoproliferative anemia of uncomplicated chronic renal disease.

  • Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. Ibrahim, Hassan N.; Ishani, Areef; Haifeng Guo; Gilbertson, David T. // Nephrology Dialysis Transplantation;Oct2009, Vol. 24 Issue 10, p3138 

    Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics